Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly owned stepdown subsidiary, Lyfius Pharma Private Limited, has restarted Penicillin-G production at its Kakinada, Andhra Pradesh facility with immediate effect from June 29, 2025. The restart follows receipt of the renewed 'Consent to Operate' (CTO) from the Andhra Pradesh Pollution Control Board (APPCB), which had been awaited since the previous intimations dated April 28, 2025 and May 26, 2025. The facility had paused operations pending this regulatory clearance. Lyfius is a key subsidiary for Aurobindo's penicillin-based active pharmaceutical ingredients business.
Positive for Aurobindo Pharma shareholders as the resumption removes a regulatory overhang and restores revenue contribution from the Penicillin-G plant. Investors should expect normalized production output and supply to downstream formulations in the coming quarters.